Novel Pyridothienopyrimidine Derivatives: Design, Synthesis and Biological Evaluation as Antimicrobial and Anticancer Agents. 2022

Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
Department of Therapeutic Chemistry, National Research Centre, Cairo 12622, Egypt.

The growing risk of antimicrobial resistance besides the continuous increase in the number of cancer patients represents a great threat to global health, which requires intensified efforts to discover new bioactive compounds to use as antimicrobial and anticancer agents. Thus, a new set of pyridothienopyrimidine derivatives 2a,b-9a,b was synthesized via cyclization reactions of 3-amino-thieno[2,3-b]pyridine-2-carboxamides 1a,b with different reagents. All new compounds were evaluated against five bacterial and five fungal strains. Many of the target compounds showed significant antimicrobial activity. In addition, the new derivatives were further subjected to cytotoxicity evaluation against HepG-2 and MCF-7 cancer cell lines. The most potent cytotoxic candidates (3a, 4a, 5a, 6b, 8b and 9b) were examined as EGFR kinase inhibitors. Molecular docking study was also performed to explore the binding modes of these derivatives at the active site of EGFR-PK. Compounds 3a, 5a and 9b displayed broad spectrum antimicrobial activity with MIC ranges of 4-16 µg/mL and potent cytotoxic activity with IC50 ranges of 1.17-2.79 µM. In addition, they provided suppressing activity against EGFR with IC50 ranges of 7.27-17.29 nM, higher than that of erlotinib, IC50 = 27.01 nM.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
April 2024, Chemistry & biodiversity,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
January 2015, European journal of medicinal chemistry,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
June 2021, Bioorganic chemistry,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
June 2014, European journal of medicinal chemistry,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
October 2004, Bollettino chimico farmaceutico,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
December 2024, Pharmaceutical biology,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
March 2010, Oncology letters,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
August 2013, Drug discoveries & therapeutics,
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
July 2021, Molecules (Basel, Switzerland),
Eman M Mohi El-Deen, and Manal M Anwar, and Amina A Abd El-Gwaad, and Eman A Karam, and Mohamed K El-Ashrey, and Rafika R Kassab
January 2016, European journal of medicinal chemistry,
Copied contents to your clipboard!